Start Date
January 31, 2011
Primary Completion Date
June 30, 2012
Study Completion Date
December 31, 2012
FP-1039
FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
Lead Sponsor
Collaborators (1)
Worldwide Clinical Trials
OTHER
Five Prime Therapeutics, Inc.
INDUSTRY